Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Total Liabilities (2016 - 2025)

ENDRA Life Sciences has reported Total Liabilities over the past 6 years, most recently at $2.1 million for Q4 2021.

  • Quarterly Total Liabilities rose 31.01% to $2.1 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2021, up 31.01% year-over-year, with the annual reading at $2.1 million for FY2021, 31.01% up from the prior year.
  • Total Liabilities was $2.1 million for Q4 2021 at ENDRA Life Sciences, down from $2.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $2.4 million in Q4 2019 and troughed at $162302.0 in Q2 2017.
  • The 5-year median for Total Liabilities is $1.7 million (2018), against an average of $1.5 million.
  • The largest YoY upside for Total Liabilities was 580.8% in 2018 against a maximum downside of 55.31% in 2018.
  • A 5-year view of Total Liabilities shows it stood at $848214.0 in 2017, then increased by 14.9% to $974583.0 in 2018, then soared by 147.86% to $2.4 million in 2019, then tumbled by 33.94% to $1.6 million in 2020, then skyrocketed by 31.01% to $2.1 million in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Total Liabilities are $2.1 million (Q4 2021), $2.2 million (Q3 2021), and $2.3 million (Q2 2021).